IMMUNEONCO-B (01541) announced that the first patient in the Phase 1 clinical trial of IMC-003/IMM72 has been successfully dosed, marking a significant milestone in the group's clinical research of IMC-003/IMM72 and establishing a solid foundation for subsequent clinical trials.
IMC-003/IMM72 is a genetically modified next-generation activin receptor IIA-Fc (ActRIIA-Fc) fusion protein with enhanced activity and quality. The group holds global intellectual property rights as well as development and commercialization rights for IMC-003/IMM72.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.